T. Barbui, G. Finazzi, and A. Carobbio, Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia

, Blood, vol.120, issue.26, pp.5128-5133, 2012.

F. Passamonti, J. Thiele, and F. Girodon, A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment, Blood, vol.120, issue.6, pp.1197-1201, 2012.

A. M. Vannucchi, T. L. Lasho, and P. Guglielmelli, Mutations and prognosis in primary myelofibrosis, Leukemia, vol.27, issue.9, pp.1861-1869, 2013.

P. Guglielmelli, T. L. Lasho, and G. Rotunno, MIPSS70: mutationenhanced international prognostic score system for transplantationage patients with primary myelofibrosis, J Clin Oncol, vol.36, issue.4, pp.310-318, 2018.

D. Pietra, E. Rumi, and V. V. Ferretti, Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms, Leukemia, vol.30, issue.2, pp.431-438, 2016.

E. Abdelhamid, M. Figeac, and A. Renneville, Quantification of JAK2V617F mutation by next-generation sequencing technology, Am J Hematol, vol.88, issue.6, pp.536-537, 2013.

T. Barbui, G. Barosi, and G. Birgegard, Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from european LeukemiaNet, J Clin Oncol, vol.29, issue.6, pp.761-770, 2011.

J. Asp, B. Andréasson, and U. Hansson, Mutation status of essential thrombocythemia and primary myelofibrosis defines clinical outcome, Haematologica, vol.101, issue.4, pp.129-132, 2016.

X. Cabagnols, F. Favale, and F. Pasquier, Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients, Blood, vol.127, issue.3, pp.333-342, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01258942

M. Brecqueville, J. Rey, and F. Bertucci, Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12 and TET2 in myeloproliferative neoplasms, Genes Chromosomes Cancer, vol.51, issue.8, pp.743-755, 2012.

L. Paz, D. Chauveau, A. Boyer, and F. , Sequential analysis of 18 genes in polycythemia vera and essential thrombocythemia reveals an association between mutational status and clinical outcome, Genes Chromosomes Cancer, vol.56, issue.5, pp.354-362, 2017.
URL : https://hal.archives-ouvertes.fr/inserm-01500343

S. Jaiswal, P. Fontanillas, and J. Flannick, Age-related clonal hematopoiesis associated with adverse outcomes, N Engl J Med, vol.371, issue.26, pp.2488-2498, 2014.

C. A. Ortmann, D. G. Kent, and J. Nangalia, Effect of mutation order on myeloproliferative neoplasms, N Engl J Med, vol.372, issue.7, pp.601-612, 2015.

P. Guglielmelli, A. Pacilli, and G. Rotunno, Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis, Blood, vol.129, issue.24, pp.3227-3236, 2017.

A. Tefferi, T. L. Lasho, and P. Guglielmelli, Targeted deep sequencing in polycythemia vera and essential thrombocythemia, Blood Adv, vol.1, issue.1, pp.21-30, 2016.

P. Lundberg, A. Karow, and R. Nienhold, Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms, Blood, vol.123, issue.14, pp.2220-2228, 2014.

R. Rampal, J. Ahn, A. -. Wahab, and O. , Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms, Proc Natl Acad Sci, vol.111, issue.50, pp.5401-5410, 2014.

A. Alvarez-larrán, A. Senín, and C. Fernández-rodríguez, Impact of genotype on leukaemic transformation in polycythaemia vera and essential thrombocythaemia, Br J Haematol, vol.178, issue.5, pp.764-771, 2017.